Novo Holdings-backed Adcendo secures $135M for ADC pipeline

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) candidates into the clinic.

California-based investor TCGX led the oversubscribed series B financing, with new investors TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Citadel’s Surveyor Capital and Logos Capital in tow, according to a Nov. 25 release.